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Background: Diabetes mellitus is the most common chronic endocrine disorder, affecting an estimated population
of 382 million people worldwide. It is associated with microvascular and macrovascular complications, including
diabetic nephropathy (DN); primary cause of end-stage renal disease. Different inflammatory and angiogenic molecules
in various pathways are important modulators in the pathogenesis and progression of diabetic nephropathy.
Differential disease risk in DN may be partly attributable to genetic susceptibility. In this meta-analysis, we aimed
to determine which of the previously investigated genetic variants in these pathways are significantly associated
with the development of DN and to examine the functional role of these genes.
Methods: A systematic search was conducted to collect and analyze all studies published till June 2013; that
investigated the association between genetic variants involved in inflammatory cytokines and angiogenesis and
diabetic nephropathy. Genetic variants associated with DN were selected and analyzed by using Comprehensive
Meta Analysis software. Pathway analysis of the genes with variants showing significant positive association with
DN was performed using Genomatix Genome Analyzer (Genomatix, Munich, Germany).
Results: After the inclusion and exclusion criteria for this analysis, 34 studies were included in this meta-analysis.
11 genetic variants showed significant positive association with DN in a random-effects meta-analysis. These
included genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10. rs1800871 (T)
genetic variant in IL-10 showed protective effect for DN. Most of these eleven genetic variants were involved in
GPCR signaling and receptor binding pathways whereas four were involved in chronic kidney failure. rs833061
[OR 2.08 (95% CI 1.63-2.66)] in the VEGFA gene and rs3917887 [OR 2.04 (95% CI 1.64-2.54)] in the CCL2 gene
showed the most significant association with the risk of diabetic nephropathy.
Conclusions: Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8,
ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy. Gene Ontology or pathway
analysis showed that these genes may contribute to the pathophysiology of DN. The functional relevance of the
variants and their pathways can lead to increased biological insights and development of new therapeutic
targets.
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Diabetes mellitus (DM) is a set of metabolic disorders
characterized by hyperglycemia resulting from defects in
insulin secretion and/or action. The prevalence of the
disease, which is becoming a major world-wide health
problem, is increasing rapidly [1]. In 2013, 382 million
cases of DM worldwide were estimated, and that num-
ber is expected to increase to 592 million cases in 2035
[1]. Diabetes mellitus is associated with microvascular
and macrovascular complications, including diabetic ne-
phropathy (DN), a primary cause of end-stage renal dis-
ease (ESRD) [2]. Due to the global increase in prevalence
of diabetes there has been a concomitant rise in the num-
ber of patients with diabetic nephropathy (DN) indicating
a prevalence of 30-40% of the patients with type 1
(T1DM) and type 2 diabetes (T2DM) being affected [3].
Mostly, individuals with long durations of diabetes and
poor glycemic control develop progressive diabetic ne-
phropathy. However, some patients appear to be at in-
creased risk while others remain relatively protected [4].
Genetic predisposition plays an important role in the
risk to developing diabetic nephropathy though the inci-
dence and severity is affected by the extent of control of
the abnormal metabolic state associated with diabetes
mellitus [5].
In recent years, there has been an increased under-
standing of the genetic and molecular basis of develop-
ment and progression of diabetic nephropathy. Although
diabetic nephropathy is traditionally considered a non-
immune disease, recent findings indicate a significant
role of immune-mediated inflammatory processes in the
pathophysiology of diabetic nephropathy. These include
the up-regulation of inflammatory mediators, higher
urinary levels of monocyte chemoattractant protein-1
and increasing macrophage influx with the progression
of diabetic nephropathy [6-8]. In streptozotocin (STZ)
diabetic rats, an increase in glomeruli capillaries area was
observed in comparison to normal age-matched controls,
implying a pronounced angiogenic reaction to the diabetic
condition [9]. Higher concentration of angiogenic markers,
vascular endothelial growth factor (VEGF) and trans-
forming growth factor β (TGF β) in plasma and urine of
diabetic nephropathy patients, emphasize the role of
angiogenesis [10,11]. Chen and Ziyadeh, [12] reported
attenuation of diabetic albuminaria by blockade of
VEGF signaling pathway. Further, a recent study showed
anti-angiogenic and anti-inflammatory DNA vaccin-
ation ameliorates the progression of glomerular path-
ology in an animal model of diabetic nephropathy [13].
As inflammation and angiogenesis play a crucial role in
the pathomechanism of diabetic nephropathy, many
studies have investigated the association of genetic poly-
morphism in these pathway genes with the risk of diabetic
nephropathy. However, there is a lack of consistencyamong the reported studies due to small sample size, lim-
ited power and sparseness of data. Therefore, the aim of
this meta-analysis is to analyze all published studies that
investigated the association of genetic variants involved in
inflammatory cytokines and angiogenesis with diabetic ne-




The articles relevant to this study were searched from
PubMed, Embase and Cochrane Library in June, 2013.
Different possible variations and combinations of the
following search terms were used: ‘diabetes mellitus’,
‘diabetic nephropathy’, ‘ESRD’, ‘inflammatory cytokines’,
‘angiogenesis’, ‘genetic variants’, ‘polymorphism’, ‘SNPs’
and ‘gene’. Additional search query was used by com-
bining the names of the specific genes and genetic vari-
ants with the term ‘diabetic nephropathy’. The reference
list of each relevant publication was also examined to
identify additional studies appropriate for inclusion in
the meta-analysis. In the initial search no filter for lan-
guage preference was used.
Inclusion and exclusion criteria
Only those studies were included in which the cases had
diabetes mellitus with macroalbuminuria, overt protein-
uria, ESRD due to diabetic nephropathy or diabetic ne-
phropathy identified by biopsy and controls had diabetic
mellitus with normoalbuminaria after > 10 years of dia-
betes duration. Cases with macroalbuminaria and/or overt
proteinuria and/or ESRD were merged together for com-
parison with controls. The selected studies should provide
detailed genotypic data of the genes in the inflammatory
and angiogenic pathways. Only articles in English language
were included. The cases and controls in the studies in-
cluded were matched by duration of diabetes and/or age.
Lack of information related to the distribution of geno-
types or alleles within the case and control groups is one
of our exclusion criteria. Studies in which the controls
were non-diabetic and/or there was comparison of differ-
ent stages of diabetic nephropathy were excluded. Review
and meta-analysis articles were excluded.
Data extraction and Statistical analysis
Following information was extracted from each selected
study like PMID No, first author’s surname, journal &
year of publication, sample size, ethnicity, methodology,
type and duration of diabetes, criteria for diabetic ne-
phropathy and frequency of alleles.
For each SNP, the allelic data from different studies
was pooled and minor allele frequencies were calculated
and compared between cases and controls. Data were
entered into a database and a statistical analysis was
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The pooled odds ratio was used to estimate the associ-
ation between the genetic variants and diabetic nephrop-
athy in this meta-analysis. The Odds Ratio (OR), at allele
level and statistically significant P-values were validated
for all the studies and recalculated for some of them, in
order to remove any adjustments made within each
study in cases where two different groups merged to-
gether, such as in the case of macroalbuminaria and
ESRD groups. A p-value <0.05 was considered to be sta-
tistically significant. Deviation from Hardy–Weinberg
equilibrium (HWE) was tested using the De Finetti pro-
gram (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) for all the
studies. The percentage of variation across studies due
to heterogeneity rather than chance was estimated via
Higgins I2 statistics using Comprehensive Meta Analysis
Version 2.0 software (Biostat, Englewood NJ, 2005). I2 is
estimated by the ratio (Q-df)/Q, where Q is the Cochran’s
Q statistic and df is degrees of freedom. I2 lies between 0
and 100% with values over 50% indicating high heterogen-
eity [14]. The random-effects model was performed using
Comprehensive Meta Analysis Version 2.0 software. The
random effects model assumes that there is a different
underlying effect size for each study. Random effects
model takes into account the diversity between the studies
and is preferred in majority of genetic association studies.
Random effects model is generally used in the presence or
anticipation of any heterogeneity between studies [15].
The sub-group analysis was performed for diabetes melli-
tus type (type 1 or type 2), diabetic nephropathy stage
(established diabetic nephropathy or advanced diabetic ne-
phropathy) and ethnicity (European or Asian origin). The
genes showing association with diabetic nephropathy were
used as input core data for Genomatix Pathway Analysis
(Genomatix, Munich, Germany).
Results
The initial literature search yielded 751 citations with
111 involving inflammatory cytokines and angiogenesis
related to diabetic nephropathy in humans. 25 research
articles representing 34 different studies were selected
after exclusion of studies which included progression of
nephropathy, meta-analysis, reviews etc. The selected 34
studies contained 55 genetic variants in 18 genes of in-
flammatory cytokines and angiogenesis which were asso-
ciated with diabetic nephropathy. Table 1 includes the
details and references of all the studies used in this meta-
analysis. The detailed information of the studied SNPs
and the corresponding pooled odds ratios and p-values
are presented in Additional file 1a, b, c, d and e.
Of the 55 genetic variants involved in the inflammatory
cytokines and angiogenesis, 11 genetic variants in or near
9 genes were significantly associated with diabetic ne-
phropathy after random-effects meta-analysis. Figure 1 isa Forest plot representation of the significantly associated
genetic variants with diabetic nephropathy- VEGFA,
CCR5 (Chemokine Receptor 5), CCL2 (Chemokine ligand
2), IL-1 (Interleukin-1), MMP9 (Matrix Metallopeptidase
9), EPO (Erythropoietin), IL-8 (Interleukin-8), ADIPOQ
(Adiponectin, C1Q And Collagen Domain Containing) and
IL-10 (Interleukin-1). The odds ratios of the significant as-
sociations with diabetic nephropathy were between the
range of 1.24 to 2.08 for increased risk effect. After meta-
analysis, 2 genetic variants- rs833061 in the VEGFA gene
and rs3917887 in the CCL2 gene showed the most signifi-
cant association with risk of diabetic nephropathy. Genetic
variant rs833061 was analyzed in 2 Irish studies resulting
in a pooled odds ratio of 2.08 (95% CI 1.63-2.66). For
rs3917887, the pooled OR was 2.04 (95% CI 1.64-2.54) ob-
tained from 2 Indian studies. rs833061 showed significant
association in type 2 diabetes mellitus whereas rs3917887
was studied in type 1 diabetes mellitus. Genetic variant
rs1799987 in CCR5 was the most studied SNP with ten
studies of which six were of caucasian and four Asian. Five
studies involved type 1 diabetes mellitus while the other
five included type 2 diabetes mellitus resulting in a pooled
odds ratio of 1.29 (95% CI 1.20-1.38). Figures 2 and 3
show the association of variants with diabetic nephropathy
among sub-groups. The significant association between
rs1799987 and diabetic nephropathy was reproduced in
type 2 diabetes mellitus, Asian, Caucasian and established
diabetic nephropathy subgroups. This association was not
significant in the type 1 diabetes mellitus and advanced
diabetic nephropathy subgroups. Other significantly asso-
ciated genetic variant, rs333 (Del32) in the CCR5 gene
had a pooled odds ratio of 1.24 (95% CI 1.08-1.43) from
four studies. Among these four studies, two Asian studies
involved type 2 diabetes mellitus whereas two Caucasian
studies were for type 1 diabetes mellitus. The association
was reproduced in the subgroup analysis (Figure 2).
The genetic variant rs17300539 in ADIPOQ gene was
studied in four european studies, all involving type 1 dia-
betes mellitus. rs17300539 was significantly associated
with diabetic nephropathy with a pooled odds ratio of 1.35
(95% CI 1.09-1.68). rs4073 SNP in IL-8 gene had a pooled
OR of 1.45 (95% CI 1.16-1.82) from two Indian studies in-
volving type 2 diabetes mellitus. In the same Indian stud-
ies, another genetic variant rs17576 in the MMP9 gene
was significantly associated with diabetic nephropathy
with a pooled OR of 1.91 (95% CI 1.54-2.38). The genetic
variant rs3025039 in the VEGF gene was found to be sig-
nificantly associated with diabetic nephropathy with a
pooled OR of 1.63 (95% CI 0.98-2.70). Two studies in the
Korean population investigated rs3025039 in type 2 dia-
betic patients. The genetic variant rs1617640 in the EPO
gene was investigated in three American studies in which
one study included type 2 diabetes mellitus whereas other
two were for type 1 diabetes mellitus. After meta-analysis,
Table 1 Details of the genes and studies in this meta-analysis study
Gene SNP Article No. of studies Population Case definition T1D/T2D ORa
CCR5 (Chemokine Receptor 5) rs7637813 Pettigrew et al, [16] 1 Irish EDNb 1 1.173(0.932-1.478)
10577983 Pettigrew et al, [16] 1 1.163(0.935-1.447)
rs2227010 Pettigrew et al, [16] 1 1.0(0.805-1.248)
rs17765882 Pettigrew et al, [16] 1 1.501(0.980-2.298)
rs2734648 Tregouet et al, [17] 3 Danish EDN 1 0.969(0.788-1.191)
Tregouet et al, [17] Finnish EDN 1 1.186(0.947-1.486)
Tregouet et al, [17] French EDN 1 1.082(0.853-1.373)
Del 32/rs333 Ahluwalia et al, [18] 4 North Indian EDN 2 2.58 (1.98–3.37)
Ahluwalia et al, [18] South Indian EDN 2 0.88 (0.51–1.5)
Pettigrew et al, [16] Irish EDN 1 1.242(0.859-1.794)
Mlynarski et al, [19] American ADNc 1 0.959(0 .652 1.410)
59029 G.A/rs1799987 Pettigrew et al, [16] 10 Irish EDN 1 1.017(0.818-1.263)
Ahluwalia et al, [18] North Indian EDN 2 2.22 (1.71–2.87)
Ahluwalia et al, [18] South Indian EDN 2 2.17 (1.43–3.29)
Buraczynska et al, [20] Polish EDN 2 1.83(1.43-2.34)
Mlynarski et al, [19] American ADN 1 0.904(0.664- 1.23)
Nakajima et al, [21] Japanese EDN 2 1.179(0.855-1.627)
Tregouet et al, [17] Danish EDN 1 1.112(0.918-1.348)
Tregouet et al, [17] Finnish EDN 1 1.152(0.938-1.415)
Tregouet et al, [17] French EDN 1 1.063(0.845-1.336)
Prasad et al, [22] Indian ADN 2 1.379(1.047-1.818)
ADIPOQ (Adiponectin, C1Q And
Collagen Domain Containing)
rs266729 Zhang et al, [23] 2 European EDN + ADN 1 1.120(0.929-1.35)
Wu et al, [24] Taiwanese EDN 2 1.39(1.0-1.9)
rs17300539 Vionnet et al, [25] 4 Danish EDN and Retd 1 1.348(0.965-1.884)
Vionnet et al, [25] Finnish EDN and Ret 1 1(0.570-1.754)
Vionnet et al, [25] French EDN and Ret 1 1.472(0.998-2.171)
Prior et al, [26] British EDN and Ret 1 1.924 (1.024-3.617)
IL8 (Interleukin-8) rs4073 Ahluwalia et al, [18] 2 North Indian EDN 2 1.44 (1.1–1.88)




















Table 1 Details of the genes and studies in this meta-analysis study (Continued)
CCL2 (Chemokine ligand 2) rs1024611 Ahluwalia et al, [18] 2 North Indian EDN 2 1.04 (0.8–1.36)
Joo et al, [27] Korean ADN 2 0.91(0.65-1.2)
rs3917887 Ahluwalia et al, [18] 2 North Indian EDN 2 2.03 (1.57–2.63)
Ahluwalia et al, [18] South Indian EDN 2 1.7 (1.12–2.57)
MMP9 (Matrix Metallopeptidase 9) rs17576 Ahluwalia et al, [18] 2 North Indian EDN 2 1.81 (1.40–2.34)
Ahluwalia et al, [18] South Indian EDN 2 2.19 (2.45–3.31)
IL-10 (Interleukin-10) –592C/A/rs1800872 Arababadi et al, [28] 2 Iranian EDN 2 1.484(0.944-2.331)
Ezzidi et al, [2]/ Mtiraoui et al, [29] Tunisian EDN 2 0.915(0.751-1.114)
–819C/T/rs1800871 Ezzidi et al, [2]/ Mtiraoui et al, [29] 1 0.777(0.631-0.958)
–1082G/A/rs1800896 Ezzidi et al, [2]/ Mtiraoui et al, [29] 1 0.841(0.694-1.018)
IL-1 (Interleukin-1) IL1A Loughrey et al, [30] 1 Caucasian EDN 1 0.66 (0.42-1.04)
IL1B Loughrey et al, [30] 1 1.971(1.221-3.182)
IL1RI Loughrey et al, [30] 1 0.94(0.618-1.429)
VEGFA (Vascular endothelial
growth factor A)
- 2549 I/D/rs35569394 Yang et al, [31] 2 British EDN and Ret 1 1.619(1.038-2.525)
Buraczynska et al, [32] Polish EDN 2 1.09(0.77-1.54)
+405/rs2010963 Buraczynska et al, [32] 2 Polish EDN 2 0.949(0.658-1.369)
McKnight et al, [33] Irish EDN and Ret 1 0.88 (0.69-1.12)
-1499C > T/rs833061 McKnight et al, [33] 2 Irish EDN and Ret 1 2.08(1.63-2.66)
-2578C > A/rs699947 McKnight et al, [33] 2 Irish EDN and Ret 1 0.92(0.72-1.17)
rs2146323 Tregouet et al, [17] 3 Danish EDN 1 0.899(0.732-1.105)
Tregouet et al, [17] Finnish EDN 1 0.914(0.739-1.131)
Tregouet et al, [17] French EDN 1 0.854(0.667-1.095)
rs3024997 Tregouet et al, [17] 3 Danish EDN 1 0.967(0.786-1.191)
Tregouet et al, [17] Finnish EDN 1 0.986(0.773-1.257)
Tregouet et al, [17] French EDN 1 1.124(0.879-1.438)
rs3025000 Tregouet et al, [17] 3 Danish EDN 1 0.962(0.781-1.186)
Tregouet et al, [17] Finnish EDN 1 0.974(0.765-1.240)
Tregouet et al, [17] French EDN 1 1.087(0.843-1.402)
936C/T/rs3025039 Kim et al, [34] 2 korean EDN + ADN 2 1.632(0.984-2.708)
VEGFB (Vascular endothelial
growth factor B)
rs12366035 Tregouet et al, [17] 3 Danish EDN 1 0.784(0.633-0.971)
Tregouet et al, [17] Finnish EDN 1 0.92(0.727-1.163)




















Table 1 Details of the genes and studies in this meta-analysis study (Continued)
VEGFC (Vascular endothelial
growth factor C)
rs585706 Tregouet et al, [17] 3 Danish EDN 1 0.8(0.562-1.139)
Tregouet et al, [17] Finnish EDN 1 1.318(0.917-1.895)
Tregouet et al, [17] French EDN 1 1.271(0.882-1.832)
IL-6 (Interleukin-6) rs2069827 Ng et al, [35] 1 Caucasian EDN + ADN 2 0.65(0.365-1.159)
rs1800796 Ng et al, [35] 0.935(0.588-1.487)
rs1800795 Ng et al, [35] 0.829(0.623-1.104)
rs2069837 Ng et al, [35] 0.865(0.54-1.384)
rs2069840 Ng et al, [35] 0.916(0.686-1.225)
rs2069861 Ng et al, [35] 1.505(0.882-2.569)
TGF-B1 (Transforming
growth factor beta 1)
rs1800470 Jahromi et al, [36] 8 Caucasian EDN 1 1.06(0.64-1.7)
Ahluwalia et al, [18] North Indian EDN 2 1.1 (0.83–1.44)
Ng et al, [37] Caucasian EDN + ADN 1 0.923(0.722–1.180)
McKnight et al, [33] Irish EDN 1 1.2(0.7-2.1)
Tregouet et al, [17] Danish EDN 1 0.979(0.799-1.199)
Tregouet et al, [17] Finnish EDN 1 1.068(0.852-1.338)
Tregouet et al, [17] French EDN 1 1.034(0.816-1.311)
Salgado et al, [38] Mexican EDN + ADN 2 1.30(0.99-1.71)
Tyr81His/rs111033611 Ahluwalia et al, [18] 1 North Indian EDN 2 1.14 (0.53–2.46)
915 G > C/rs1800471 Ng et al, [37] 3 Caucasian EDN + ADN 2 1.022(0.627–1.665)
McKnight et al, [33] Irish EDN 1 1.0(0.66-1.5)
Salgado et al, [38] Mexican EDN + ADN 2 4.17(1.40-12.3)
-800 A > Grs1800468 Ng et al, [37] 4 Caucasian EDN + ADN 2 1.178(0.762–1.821)
McKnight et al, [33] Irish EDN 1 0.75(0.45-1.2)
Prasad et al, [22] Indian ADN 2 1.04(0.816-1.325)
Salgado et al, [38] Mexican EDN + ADN 2 0.98(0.46-2.09)
rs1800469 Ng et al, [37] 3 Caucasian EDN + ADN 2 1.088(0.841–1.407)
McKnight et al, [33] Irish EDN 1 0.94(0.58-1.5)
Prasad et al, [22] Indian ADN 2 0.738(0.50-1.091)
rs1800472 Ng et al, [37] 1 Caucasian EDN + ADN 2 1.168(0.639–2.135)
rs2241717 Tregouet et al, [17] 3 Danish EDN 1 0.957(0.787-1.164)
Tregouet et al, [17] Finnish EDN 1 1.068(0.864-1.322)




















Table 1 Details of the genes and studies in this meta-analysis study (Continued)
rs8179181 Tregouet et al, [17] 3 Danish EDN 1 1.193(0.957-1.488)
Tregouet et al, [17] Finnish EDN 1 1.022(0.799-1.308)
Tregouet et al, [17] French EDN 1 0.944(0.722-1.234)
TGF-BR1
(TGF beta receptor 1)
rs1571589 Tregouet et al, [17] 3 Danish EDN 1 0.951(0.746-1.213)
Tregouet et al, [17] Finnish EDN 1 1.111(0.836-1.476)
Tregouet et al, [17] French EDN 1 1.018(0.766-1.352)
rs928180 Tregouet et al, [17] 3 Danish EDN 1 1.362(0.988-1.877)
Tregouet et al, [17] Finnish EDN 1 0.92(0.67-1.263)
Tregouet et al, [17] French EDN 1 0.901(0.608-1.334)
TGF-BR2
(TGF beta receptor 2)
747C > G/rs11466531 McKnight et al, [33] 1 Irish EDN 1 1.37(1.0-1.89)
1149G > A/ss50394788 McKnight et al, [33] 1 Irish EDN 1 2.432(0.81-7.303)
CCR2 (chemokine
receptor type 2)
G46295A/rs1799864 Joo et al, [27] korean ADN 2 0.91(0.65-1.2)
rs1799865 Prasad et al, [22] 1 Indian ADN 2 1.551(0.901-2.671)
RANTES/CCL5
(Chemokine ligand 5)
C-28G/rs2280788 Joo et al, [27] 2 korean ADN 2 0.97(0.65-1.4)
Nakajima et al, [21] Japanese EDN 2 1.532(1.004-2.338)
ss161639200 Pettigrew et al, [16] 1 irish EDN 1 1.140(0.821-1.584)
rs9898132 Pettigrew et al, [16] 1 Irish EDN 1 1.092(0.746-1.599)
G-403A/rs2107538 Joo et al, [27] 3 Korean ADN 2 0.8(0.59-1.0)
Pettigrew et al, [16] Irish EDN 1 1.085(0.81-1.452)
Nakajima et al, [21] Japanese EDN 2 0.88(0.632-1.225)
EPO (Erythropoietin) rs1617640 Tong et al, [39] 3 American EDN + ADN 2 1.446(1.145-1.826)
Tong et al, [39] 1 1.535(1.320-1.787)
Tong et al, [39] 1 1.382(1.050-1.820)
TNFα (Tumor necrosis factor) -308/rs1800629 Prasad et al, [22] 1 Indian ADN 2 1.383(0.775-2.468)
aOR, Odds ratio (95% CI); bEDN, established diabetic nephropathy; cADN, advanced diabetic nephropathy; dRet, retinopathy.




















Figure 1 Forest Plot for genetic variants involved in inflammatory cytokines and angiogenesis and significantly associated with
diabetic nephropathy after meta-analysis.
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http://www.biomedcentral.com/1471-2350/15/103the pooled OR of 1.47 (95% CI 1.31-1.65) showed a signifi-
cant association with diabetic nephropathy. There was
only one study in type 1 diabetes Caucasian population
for the SNP IL1B in the IL-1 gene. IL1B showed a signifi-
cant association with risk of diabetic nephropathy having
an OR of 1.97 (95% CI 1.22-3.18).
In this meta-analysis, there was only one SNP which
had a protective effect against diabetic nephropathy.
Genetic variant rs1800871 in the IL-10 gene was studied
in a Tunisian study and had an OR of 0.77 (95% CI 0.63-
0.98). In our meta-analysis, there were 44 genetic vari-
ants in the genes involved in inflammatory cytokines
and angiogenesis that were not found to be significantly
associated with DN (Figure 4). It is important to men-
tion that among the 44 SNPs, only 22 were investigated
in two or more than two studies while the others had a
single study each. Genetic variant rs1800470 showed a
significant association with diabetic nephropathy in theFigure 2 Genetic variants significantly associated with diabetic
nephropathy after meta-analysis in a subgroup; T1D- type 1
diabetes mellitus, T2D- type 2 diabetes mellitus, Cau-Caucasian
origin, EDN- established diabetic nephropathy.type 2 diabetes mellitus subgroup with an OR of 1.25
(95% CI 1.04-1.51) (Figure 2).
For this meta-analysis, genes showing significant associ-
ation with diabetic nephropathy were analyzed to assess
their contribution in different functional pathways. G pro-
tein coupled-receptors (GPCRs) or seven-transmemebrane
receptors are the most prevailing class of signaling trans-
duction molecules in humans. In the GPCR signaling
pathways, inflammatory cytokine and angiogenic genes
positively associated with diabetic nephropathy encode
proteins present on the extra-cellular membrane. Among
the nine genes showing significant association with dia-
betic nephropathy in our study- IL10, VEGFA, EPO, IL1
and IL8 were a part of GPCR signaling pathway (Figure 5).
In the molecular function based pathway, VEGFA, EPO,
IL1, IL8, IL10, ADIPOQ and CCL2 were involved in re-
ceptor binding. EPO and ADIPOQ are inhibited by TNFFigure 3 Genetic variants not significantly associated with diabetic
nephropathy after meta-analysis in a subgroup; T1D- type 1
diabetes mellitus, T2D- type 2 diabetes mellitus, EDN- established
diabetic nephropathy, ADN- advanced diabetic nephropathy.
Figure 4 Forest Plot for genetic variants involved in inflammatory cytokines and angiogenesis and not significantly associated with
diabetic nephropathy after meta-analysis.
Figure 5 Genes involved in GPCR signaling Pathway: (G protein coupled-receptors are seven-transmemebrane receptors involved in
signal transduction in humans).
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Figure 6 Genes involved in receptor binding pathway.
Nazir et al. BMC Medical Genetics 2014, 15:103 Page 10 of 14
http://www.biomedcentral.com/1471-2350/15/103(Tumor necrosis factor) , whereas, other genes are acti-
vated by TNF. VEGFA is activated by SMAD3 (Mothers
against decapentaplegic homolog 3) present in the
intra-cellular region (Figure 6). Disease pathway analysis
showed IL6, EPO, ADIPOQ and CCR2 to be involved in
chronic kidney failure. The hierarchical layout shows that
IL6, EPO, ADIPOQ and CCR2 function by influencing
angiotensin I-converting enzyme (ACE) gene expression.
ACE further interacts with G-protein beta3-subunit (GNB3)
and this interaction is also associated with hypertension in
many populations (Figure 7).
Publication Bias
Thirty six genetic variants were lacking a good number
of studies (i.e. less than three studies), thus it was not
possible to calculate the publication bias. Of the other
nineteen studies, six SNP studies (ADIPOQ rs17300539;
RANTES rs2107538; TGF-B1 rs1800468; TGF-B1 rs2241717;
VEGFA rs3024997; VEGFA rs3025000) did not account
for publication bias as evident from the symmetric fun-
nel plot and thirteen did show evidence of publication
bias (Additional file 2).Figure 7 Genes involved in chronic kidney failure (Disease Pathway).Discussion
This meta-analysis, including 55 genetic variants in 18
genes from 34 published studies, explored the association
between the genetic variants within the genes involved in
inflammatory cytokines and angiogenesis pathways and
diabetic nephropathy. The results showed that 11 gen-
etic variants were significantly associated with diabetic
nephropathy.
Cytokines act as pleiotropic polypeptides regulating
inflammatory and immune responses through actions
on cells. The relationships between inflammation and
the development and progression of diabetic nephropathy
involve complex molecular networks and processes. Many
studies have shown a strong association of circulating in-
flammatory markers and proinflammatory cytokines with
the risk of developing of diabetic complications [40]. Evi-
dence from studies where immunosuppressive strategies
reduce renal macrophage accumulation and attenuate the
development of diabetic nephropathy, support the role of
inflammation in diabetic complications [40].
Angiogenesis, the formation of new blood vessels from
pre-existing vasculature, has been implicated in the genesis
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phropathy. Several studies have reported an increase in
potent stimulators of angiogenesis in diabetic nephrop-
athy [41,42]. In addition, the therapeutic efficacies of
anti–angiogenic strategies have further demonstrated
the involvement of angiogenesis in the progression of
diabetic nephropathy [13,43]. In this context, genetics
of inflammatory cytokines and angiogenesis is import-
ant to analyze the involved genes and their role in sus-
ceptibility to diabetic nephropathy.
In this meta-analysis, variants within or near VEGFA
(two variants), CCR5 (two variants), CCL2, IL-1, MMP9,
EPO, IL-8, ADIPOQ and IL-10 were significantly associ-
ated with diabetic nephropathy. Three genetic variants
(two in the VEGFA and one in the EPO gene) belonged
to angiogenesis pathway whereas the other variants
were included in inflammatory cytokines. These re-
sults support a role of the inflammatory cytokines and
angiogenesis pathways in the pathogenesis of diabetic
nephropathy.
It has been reported that there is an increased VEGF
expression in patients with diabetic nephropathy and anti-
bodies against VEGF in the early stages of experimental
diabetes can ameliorate the renal dysfunction [31]. In this
meta-analysis, two genetic variants in VEGFA gene were
significantly associated with diabetic nephropathy. Both
genetic variants were analysed in studies with moderate
sample size. and more studies are needed to establish true
effect sizes in such cases [44]. T allele of rs833061 genetic
variant in VEGFA gene was found to increase the risk of
diabetic nephropathy whereas Mooyaart et al. [44] in their
study considered C allele of rs833061 as having a protect-
ive effect.
CCL2, also known as Monocyte chemo-attractant
protein-1(MCP-1), is the strongest known chemo-tactic
factor for monocytes and is upregulated in diabetic ne-
phropathy [18]. In this meta-analysis, the insertion at
CCL2 rs3917887 showed two fold higher risk of dia-
betic nephropathy as compared to controls. Chinoy
et al. have reported the association CCL2 rs3917887
with development of inflammatory myopathies [45].
CCR5 is a β-chemokine receptor involved in a migration
of monocytes, NK cells and some T-cells to the inflamma-
tion site [20]. CCR5 rs1799987 was the most studied genetic
variant in inflammatory cytokines. This SNP is reported
to increase the protein level by increasing the transcrip-
tional activity of the CCR5 gene [46]. Also, for genetic
variant rs1799987 in CCR5 gene A allele was the risk
factor for diabetic nephropathy in our study whereas
Mooyaart et al. [44] considered G allele of rs1799987 as
a protective allele. The 32 –bp deletion in CCR5 rs333
changes the open reading frame of the gene resulting in
a trunacated protein [47]. This polymorphism showing
a significant association with DN in this meta-analysis,is shown to promote renal fibrosis instead of normal tis-
sue repair [48].
ADIPOQ encodes adiponectin, a hormone exclusively
secreted by the adipose tissue [23]. A allele of rs17300539
in the promoter of ADIPOQ is a risk factor for DN. It has
been suggested that this genetic variation may contribute
to an increased risk of developing nephropathy partly
through the increase in adiponectin levels [25].
IL-8 is a member of the CXC chemokine family and is
associated with a variety of proinflammatory activities
[49]. rs4073 lies in the regulatory region and increases
the protein level. An increase in the urinary excretion of
IL-8 in DN patients has been reported [18]. In their
study, Skov et al., showed that IL-8 is an antibody thera-
peutic target in inflammatory diseases [49].
The pro-inflammatory cytokine interleukin 1 (IL-1)
stimulates kidney mesangial cell proliferation and extra-
cellular matrix expansion, contributing to pathogenesis
of DN [30]. In this meta-analysis, there is only one study
showing allele IL1B*2 associated with a nearly two fold
higher risk of diabetic nephropathy. Additional studies
are required to establish the reported risk factor.
MMP9 rs17576 lies in the substrate binding region
and leads to over-accumulation of extracellular matrix,
leading to renal damage [18]. Rysz et al. reported an in-
crease in MMP-9 in diabetic nephropathy when compared
with diabetes with normal renal function [50].
EPO is a potent angiogenic factor involved in diabetic
micro-vascular complications [39]. Garcia et al. reported
EPO increased the rate of renal damage [51]. T allele of
genetic variant rs1617640 in EPO gene was a risk allele
for diabetic nephropathy in this meta-analysis. This find-
ing was in agreement with Williams et al. [52] who in
their study showed T allele of rs1617640 as a risk factor
for diabetic nephropathy. On the contrary, Mooyaart
et al. [44] considered T allele to have a protective effect
for diabetic nephropathy.
Interleukin-10 (IL-10) fulfils the criteria for an anti-
inflammatory and immunosuppressive cytokine [53].
Wong et al. reported a correlation between IL-10 levels
and extent of renal damage in diabetic nephropathy [54].
There were two studies investigating the protective ef-
fect of T allele of rs1800871 for diabetic nephropathy.
Both the studies were done in Tunisian population by
the same authors with apparently the same study group
(Table 1- ref. 2, 29). Since the methodology and results
were identical for the two studies, we considered them
as a single study to avoid overestimation of effects.
An important factor that bears on the interpretation of
meta-analysis of the genetics of diabetic nephropathy is
the adequacy of phenotype definition. This problem is
reflected in studies showing that most patients with type
1 diabetes categorized initially as having microalbumi-
naria, undergo regression to normoalbuminaria [52]. To
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studies where diabetic nephropathy was defined by macro-
albuminaria or ESRD. As with all meta-analysis, one major
limitation of this study is publication bias. Only published
data in journals was included in this study which may lead
to ignoring the negative or non-significant association
studies. Heterogeneity between the studies can affect the
interpretation of results. One of the potential reason for
heterogeneity is the winner’s curse, which appears as an
upward bias in the estimated effect of a newly identified
allele on disease risk when the study design lacks sufficient
statistical power. . The winner’s curse manifests mostly in
genome‐wide association (GWA) studies in which 300
000–1 000 000 single‐nucleotide polymorphisms are
tested [55]. All the studies included in this meta-analysis
were candidate gene based. Further, to minimize the over-
estimation caused by the winner’s curse, effect sizes and
minor allele frequencies were calculated from pooled esti-
mates from the initial reporting study and other subse-
quent studies. Random effects model was performed to
account for any possible heterogeneity.
In this study, enrichment analysis of the genes signifi-
cantly associated with diabetic nephropathy, generated
three functional pathways- GPCR signaling, receptor
binding and chronic kidney failure. GPCRs transduce
extracellular signals inside the cell through activation of
heterotrimeric G proteins and/or via other G protein-
independent signaling pathways. Agonist-induced GPCR
phosphorylation by G protein-coupled receptor kinases
(GRKs) are involved in a number of important systems re-
lated to the development and progression of Diabetic ne-
phropathy [56]. Presence of these genes in the functional
pathways supports their significant association with dia-
betic nephropathy as concluded in this meta-analysis.
However, further experiments are required to elucidate
the exact role of these genes in the pathogenesis of dia-
betic nephropathy.
Considering a worldwide increase in diabetes, there is
an urgent need to provide patients protection from the
development and progression of diabetic nephropathy.
Identification of genes involved in the primary mecha-
nisms contributing to onset and progression of diabetic
nephropathy is important for developing new thera-
peutic interventions. Inflammatory cytokines and angio-
genic factors play a diverse role in the pathogenesis of
diabetic nephropathy. The recognition of the genes/gen-
etic variants as having a significant association with risk
of diabetic nephropathy will provide new therapeutic tar-
gets. Furthermore, this will also help to identify patients
with increased risk of diabetic nephropathy.
Conclusions
This study identified 11 genetic variants in or near 9
genes -VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8,ADIPOQ and IL-10, significantly associated with diabetic
nephropathy. Further studies are required to better under-
stand their functional relevance in the pathogenesis of
diabetic nephropathy. These genetic variants within the
inflammatory cytokines and angiogensis pathways might
be good candidates for identifying genetic predispos-
ition to DN as well as revealing the pathogenesis of dia-
betic nephropathy.Additional files
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10; GRKs: G protein-coupled receptor kinases; GPCRs: G protein-coupled
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